Next-Generation AI-Powered Technology Offers New Option for Treating Enlarged Prostate

DELRAY BEACH, Fla.– Delray Medical Center acquires the HYDROS™ Robotic System, the latest advancement in Aquablation® therapy for the treatment of benign prostatic hyperplasia (BPH), commonly referred to as an enlarged prostate.

The HYDROS Robotic System is an AI-powered, minimally invasive surgical platform designed to provide precise, personalized therapy for men suffering from BPH. The system utilizes real-time ultrasound guidance and waterjet technology to remove excess prostate tissue while preserving vital structures responsible for sexual function and continence.

“The addition of the HYDROS Robotic System further strengthens our commitment to bringing the latest and most effective technologies to our community,” said Heather Havericak, CEO of Delray Medical Center. “We’re proud to invest in advanced solutions that help improve quality of life for our patients and deliver better outcomes.”

BPH affects millions of men and can cause uncomfortable and disruptive urinary symptoms, including frequent urination, a weak stream, and the urge to urinate at night. If left untreated, it can lead to more serious complications. Aquablation therapy offers a clinically proven, durable solution that is effective across a wide range of prostate sizes.

Aquablation therapy is known for its ability to help men preserve:

• Erectile function: Unlike some traditional BPH treatments that can risk nerve damage due to heat, Aquablation uses a heat-free waterjet to remove obstructive prostate tissue, minimizing the risk of erectile dysfunction.
• Continence: The robotic system and real-time imaging used in Aquablation allow surgeons to precisely map out the prostate and avoid areas critical for urinary control, leading to a low risk of post-procedure incontinence.
• Ejaculation: Clinical studies have shown that a high percentage of men who receive Aquablation therapy preserve their ability to ejaculate. For example, in a five-year follow-up from the WATER study, 98% of patients preserved ejaculation. 

HYDROS represents the next evolution in Aquablation therapy, featuring advanced AI treatment planning, enhanced imaging, and a streamlined surgical workflow, helping to improve both patient and surgical team experiences.

For more information about urologic services at Delray Medical Center, visit www.palmbeachhealthnetwork.com.